Literature DB >> 22339062

In vitro synergistic interaction between DTA0100 and radiation in human cancer cell lines.

Elisa Bordon1, Leticia G Leon, Carla Rios-Luci, Pedro C Lara, Jose M Padron.   

Abstract

DTA0100 is a new catalytic inhibitor of the human DNA topoisomerase IIα that induces G2/M phase cell cycle arrest in human solid tumor cells lines from various malignancies. In our study, we investigated the effectiveness of the combined treatment of ionizing radiation with DTA0100 on the survival of three representative human solid tumor cell lines: HeLa (cervix), WiDr (colon) and SW1573 (non-small cell lung cancer). The concomitant treatment of DTA0100 and irradiation showed a synergistic and antagonistic effect in the three cell lines tested. A synergistic cytotoxic effect of the combination of DTA0100 and radiation was confirmed by the median drug effect analysis method. It was found that in those protocols where the drug was administered after radiation the most synergistic effect was achieved. Our study constitutes the first in vitro evidence for synergistic effects between DTA0100 and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with cervical, colon and non-small cell lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22339062     DOI: 10.2174/187152012802650057

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  2 in total

1.  In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.

Authors:  María Sol Brassesco; Julia Alejandra Pezuk; Andressa Gois Morales; Jaqueline Carvalho de Oliveira; Gabriela Molinari Roberto; Glenda Nicioli da Silva; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Cancer Biol Ther       Date:  2013-05-31       Impact factor: 4.742

2.  Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.

Authors:  Julia Alejandra Pezuk; María Sol Brassesco; Andressa Gois Morales; Jaqueline Carvalho de Oliveira; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Cancer Biother Radiopharm       Date:  2013-05-28       Impact factor: 3.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.